[go: up one dir, main page]

NO20045023L - Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer - Google Patents

Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Info

Publication number
NO20045023L
NO20045023L NO20045023A NO20045023A NO20045023L NO 20045023 L NO20045023 L NO 20045023L NO 20045023 A NO20045023 A NO 20045023A NO 20045023 A NO20045023 A NO 20045023A NO 20045023 L NO20045023 L NO 20045023L
Authority
NO
Norway
Prior art keywords
crystals
steroids
pharmaceutical formulations
preparation
particle size
Prior art date
Application number
NO20045023A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hosel
Uwe Mueller
Annette Eichardt
Hagen Gerecke
Sabine Gliesing
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20045023L publication Critical patent/NO20045023L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet en fremgangsmåte for fremstilling av krystaller av steroider hvis gjennomsnittlige partikkelstørrelse Ugger i et på forhånd gitt orm-åde og hvis maksimale partikkelstørrelse ikke overskrider en på forhånd gitt verdi, hvorved en overmettet oppløsning av steroidene under krystalhsasjonen underkastes en våtmaling ved hjelp av en irmretning for våtmaling, hvorved en primærkomsuspensjon oppnås. Det er videre beskrevet ved derme fremgangsmåten oppnåelige krystaller samt farmasøytiske formuleringer irmeholdende disse.
NO20045023A 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer NO20045023L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218107A DE10218107A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/004154 WO2003091272A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von steroiden, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
NO20045023L true NO20045023L (no) 2004-11-18

Family

ID=29264787

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045023A NO20045023L (no) 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Country Status (20)

Country Link
US (1) US7148212B2 (no)
EP (1) EP1497308B1 (no)
JP (1) JP4490116B2 (no)
KR (1) KR20040106380A (no)
CN (1) CN1646555A (no)
AT (1) ATE340186T1 (no)
AU (1) AU2003232491A1 (no)
BR (1) BR0309357A (no)
CA (1) CA2480004C (no)
DE (2) DE10218107A1 (no)
DK (1) DK1497308T3 (no)
ES (1) ES2274258T3 (no)
IL (1) IL163986A0 (no)
MX (1) MXPA04010467A (no)
NO (1) NO20045023L (no)
PL (1) PL371340A1 (no)
PT (1) PT1497308E (no)
RU (1) RU2315056C2 (no)
WO (1) WO2003091272A1 (no)
ZA (1) ZA200409401B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PL1886694T3 (pl) * 2006-08-10 2009-11-30 Jenapharm Gmbh Doustna postać leku do antykoncepcji
US20080038350A1 (en) * 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
DE102010003711B4 (de) * 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9745250B2 (en) 2014-05-13 2017-08-29 Akzo Nobel Chemicals International B.V. Process to crystallize chelating agents
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
JP7029875B1 (ja) 2020-05-15 2022-03-04 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) * 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
WO1990003782A2 (en) 1988-10-05 1990-04-19 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
DE3917617A1 (de) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
DE69227849T2 (de) 1991-07-10 1999-04-29 Chiyoda Corp., Yokohama Verfahren und Herstellung eines Kristallinadduktes von Bisphenol A mit Phenol und Vorrichtung dafür
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1052194C (zh) * 1993-12-27 2000-05-10 日本曹达株式会社 用于彩色显影的含有4-羟基-4'-异丙氧基二苯砜的组合物及其湿性研磨法和分散液
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
WO2000039076A1 (fr) * 1998-12-25 2000-07-06 Fuji Chemical Industries, Ltd. Procede de production de pantothenate de calcium
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
IL163986A0 (en) 2005-12-18
DE50305122D1 (de) 2006-11-02
ATE340186T1 (de) 2006-10-15
RU2004134324A (ru) 2006-02-10
EP1497308B1 (de) 2006-09-20
KR20040106380A (ko) 2004-12-17
CN1646555A (zh) 2005-07-27
MXPA04010467A (es) 2004-12-13
BR0309357A (pt) 2005-02-22
RU2315056C2 (ru) 2008-01-20
CA2480004A1 (en) 2003-11-06
ES2274258T3 (es) 2007-05-16
WO2003091272A1 (de) 2003-11-06
JP2005524698A (ja) 2005-08-18
EP1497308A1 (de) 2005-01-19
PT1497308E (pt) 2007-01-31
CA2480004C (en) 2007-11-13
DE10218107A1 (de) 2003-11-20
US20030216360A1 (en) 2003-11-20
AU2003232491A1 (en) 2003-11-10
US7148212B2 (en) 2006-12-12
PL371340A1 (en) 2005-06-13
JP4490116B2 (ja) 2010-06-23
DK1497308T3 (da) 2007-01-29
ZA200409401B (en) 2006-02-22

Similar Documents

Publication Publication Date Title
NO20045023L (no) Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer
NO20045073L (no) Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer
WO2003002196A3 (en) Multi-site ventricular pacing system measuring qrs duration
CA2369070A1 (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
ATE246702T1 (de) Verfahren zur darstellung von oligonukleotiden
CA2480080A1 (en) Composition for cell proliferation
NZ579082A (en) Stable suspensions of micronised particles of a solid organic compound which is free of surfactants, thickeners, poly-electrolytes or block copolymers
EP0073340A3 (en) Titanium dioxide pigment having improved photostability and process for producing same
CA2482021A1 (en) Removal of adenine during a process of pathogen reducing blood and blood components
RS50433B (sr) Postupak za dobijanje i upotreba sfernih klastera telitromicina za pripremanje farmaceutskih oblika
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer
ATE496868T1 (de) Verfahren zur herstellung von siliciumdioxid aus olivin
EP1142866A4 (en) METHOD FOR PURIFYING CALCIUM PANTOTHENATE
JPS5319999A (en) Production of phosphate and ammonium chloride
CA2316739A1 (en) Preparation of cells for production of biologicals
US5968249A (en) Process for preparing silica pigment
MD2133F1 (en) Process for tobacco growth stimulation
JPH07114570B2 (ja) コーティング種子及びその製造方法
ATE178051T1 (de) Verfahren zur herstellung einer physikalisch stabilen, kristallinen gamma-modifikation von para-aminobenzolsulfonamid
DuCHESNE Hybridization in the Methyl Radical of CH3X Molecules
IE791438L (en) Oxadiazolotriazines
Hawkins et al. Patterns of abundance and growth of tailed frog populations near the Mt. St. Helens blast Zone
JPS54118656A (en) Treatment method of waste water containing starch
JPS53149997A (en) Preparation of xanthine derivatives
JPS537519A (en) Concentrating method for titanium component

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application